|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
increases response to substance |
ISO |
ADAM17 results in increased susceptibility to Flufenamic Acid |
CTD |
PMID:12147693 |
|
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
decreases activity multiple interactions |
ISO |
Flufenamic Acid results in decreased activity of AKR1C1 protein Flufenamic Acid inhibits the reaction [AKR1C1 protein affects the susceptibility to Oxaliplatin]; Flufenamic Acid inhibits the reaction [AKR1C1 protein results in increased metabolism of Dihydrotestosterone] |
CTD |
PMID:8573067 PMID:12604236 PMID:14672942 PMID:23933386 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
multiple interactions decreases activity |
ISO |
Flufenamic Acid inhibits the reaction [AKR1C2 protein results in increased metabolism of Dihydrotestosterone] Flufenamic Acid results in decreased activity of AKR1C2 protein |
CTD |
PMID:8573067 PMID:12604236 PMID:14672942 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
affects binding decreases activity multiple interactions |
ISO |
Flufenamic Acid binds to AKR1C3 protein Flufenamic Acid results in decreased activity of AKR1C3 protein Flufenamic Acid inhibits the reaction [AKR1C3 protein affects the susceptibility to oxaliplatin]; Flufenamic Acid inhibits the reaction [AKR1C3 protein results in increased metabolism of Dihydrotestosterone] |
CTD |
PMID:12604236 PMID:14672942 PMID:14996743 PMID:23933386 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Ar |
androgen receptor |
multiple interactions decreases expression |
ISO |
Flufenamic Acid analog binds to and results in decreased activity of AR protein; Flufenamic Acid binds to and results in decreased activity of AR protein Flufenamic Acid results in decreased expression of AR mRNA; Flufenamic Acid results in decreased expression of AR protein |
CTD |
PMID:10537180 PMID:19645433 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Asic5 |
acid sensing ion channel subunit family member 5 |
multiple interactions |
ISO |
Flufenamic Acid binds to and results in increased activity of ASIC5 protein |
CTD |
PMID:21828194 |
|
NCBI chr 2:167,307,984...167,336,812
Ensembl chr 2:167,307,984...167,336,812
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO |
Flufenamic Acid inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAD protein] |
CTD |
PMID:27957685 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions |
ISO |
Flufenamic Acid inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAK1 protein] |
CTD |
PMID:27957685 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Best1 |
bestrophin 1 |
decreases activity |
ISO |
Flufenamic Acid results in decreased activity of BEST1 protein |
CTD |
PMID:19828819 |
|
NCBI chr 1:206,629,340...206,646,085
Ensembl chr 1:206,629,500...206,646,063
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
Flufenamic Acid inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BID protein] |
CTD |
PMID:27957685 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Flufenamic Acid inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CASP3 protein modified form] |
CTD |
PMID:27957685 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casr |
calcium-sensing receptor |
multiple interactions |
ISO |
Flufenamic Acid promotes the reaction [CASR protein results in increased uptake of Calcium] |
CTD |
PMID:21562303 |
|
NCBI chr11:64,235,251...64,304,811
Ensembl chr11:64,235,251...64,304,811
|
|
G |
Cftr |
CF transmembrane conductance regulator |
decreases activity |
ISO |
Flufenamic Acid results in decreased activity of CFTR protein |
CTD |
PMID:15277574 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
multiple interactions |
EXP |
[Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of CGA mRNA |
CTD |
PMID:8404651 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
multiple interactions |
ISO |
Flufenamic Acid inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium] |
CTD |
PMID:18316702 |
|
NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Dhrs11 |
dehydrogenase/reductase 11 |
decreases activity |
ISO |
Flufenamic Acid results in decreased activity of DHRS11 protein |
CTD |
PMID:30926317 |
|
NCBI chr10:69,698,214...69,708,294
Ensembl chr10:69,698,214...69,708,295
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
[Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of FSHB mRNA |
CTD |
PMID:8404651 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Grm1 |
glutamate metabotropic receptor 1 |
multiple interactions |
EXP |
Flufenamic Acid inhibits the reaction [3,5-dihydroxyphenylglycine results in increased activity of GRM1 protein]; Flufenamic Acid inhibits the reaction [[3,5-dihydroxyphenylglycine results in increased activity of GRM1 protein] which results in increased abundance of Calcium] |
CTD |
PMID:14622174 |
|
NCBI chr 1:5,058,285...5,453,170
Ensembl chr 1:5,058,292...5,453,170
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
Flufenamic Acid inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
Flufenamic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL1A protein] |
CTD |
PMID:10866999 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
EXP ISO |
Flufenamic Acid results in increased expression of IL6 mRNA Flufenamic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] |
CTD |
PMID:15135310 PMID:24849676 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
ISO |
E 4031 inhibits the reaction [Flufenamic Acid promotes the reaction [KCNH2 protein results in increased transport of Potassium]]; Flufenamic Acid promotes the reaction [KCNH2 protein results in increased transport of Potassium] |
CTD |
PMID:12359267 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnk10 |
potassium two pore domain channel subfamily K member 10 |
multiple interactions |
ISO |
Flufenamic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium] |
CTD |
PMID:16075240 |
|
NCBI chr 6:117,690,052...117,826,120
Ensembl chr 6:117,694,222...117,825,695
|
|
G |
Kcnk2 |
potassium two pore domain channel subfamily K member 2 |
multiple interactions |
ISO |
Flufenamic Acid promotes the reaction [KCNK2 protein results in increased transport of Potassium] |
CTD |
PMID:16075240 |
|
NCBI chr13:100,766,101...100,963,435
Ensembl chr13:100,766,113...100,963,435
|
|
G |
Kcnk4 |
potassium two pore domain channel subfamily K member 4 |
multiple interactions |
ISO |
Flufenamic Acid promotes the reaction [KCNK4 protein results in increased transport of Potassium] |
CTD |
PMID:16075240 |
|
NCBI chr 1:204,117,941...204,129,494
Ensembl chr 1:204,114,572...204,125,925
|
|
G |
Kiss1 |
KiSS-1 metastasis-suppressor |
multiple interactions |
ISO |
Flufenamic Acid inhibits the reaction [[KISS1 protein results in increased activity of KISS1R protein] which results in increased abundance of Calcium] |
CTD |
PMID:18948403 |
|
NCBI chr13:44,775,106...44,780,707
Ensembl chr13:44,774,823...44,780,612
|
|
G |
Kiss1r |
KISS1 receptor |
multiple interactions |
ISO |
Flufenamic Acid inhibits the reaction [[KISS1 protein results in increased activity of KISS1R protein] which results in increased abundance of Calcium] |
CTD |
PMID:18948403 |
|
NCBI chr 7:9,785,135...9,790,283
Ensembl chr 7:9,785,135...9,788,793
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions increases expression |
ISO |
Flufenamic Acid inhibits the reaction [Cyclosporine inhibits the reaction [[Cholesterol, LDL binds to LDLR protein] which results in increased degradation of Cholesterol, LDL]]; Flufenamic Acid promotes the reaction [[Cholesterol, LDL binds to LDLR protein] which results in increased degradation of Cholesterol, LDL]; Flufenamic Acid promotes the reaction [Cholesterol, LDL binds to LDLR protein] Flufenamic Acid results in increased expression of LDLR mRNA; Flufenamic Acid results in increased expression of LDLR protein |
CTD |
PMID:10395027 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
Flufenamic Acid inhibits the reaction [LEP protein results in increased transport of Calcium] |
CTD |
PMID:20107083 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
[Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of LHB mRNA |
CTD |
PMID:8404651 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Nkx3-1 |
NK3 homeobox 1 |
multiple interactions |
ISO |
Flufenamic Acid inhibits the reaction [mibolerone results in increased expression of NKX3-1 mRNA] |
CTD |
PMID:10537180 |
|
NCBI chr15:44,473,851...44,476,443
Ensembl chr15:44,473,851...44,476,441
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
Flufenamic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] Flufenamic Acid results in increased expression of NOS2 mRNA |
CTD |
PMID:10866999 PMID:15135310 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Panx1 |
Pannexin 1 |
decreases activity |
ISO |
Flufenamic Acid results in decreased activity of PANX1 protein |
CTD |
PMID:19023039 |
|
NCBI chr 8:11,851,176...11,889,774
Ensembl chr 8:11,850,730...11,889,774
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
Flufenamic Acid binds to and results in increased activity of PPARA protein |
CTD |
PMID:9013583 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases activity |
ISO |
[Flufenamic Acid results in increased activity of PPARG protein] which results in increased expression of PTGS2 protein; Flufenamic Acid binds to and results in increased activity of PPARG protein |
CTD |
PMID:9013583 PMID:10866999 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
ISO |
[Flufenamic Acid results in increased activity of PPARG protein] which results in increased expression of PTGS2 protein; Flufenamic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; Flufenamic Acid inhibits the reaction [TNF protein results in increased expression of PTGS2 protein] Flufenamic Acid results in increased expression of PTGS2 mRNA; Flufenamic Acid results in increased expression of PTGS2 protein |
CTD |
PMID:10866999 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Sell |
selectin L |
decreases expression |
ISO |
Flufenamic Acid results in decreased expression of SELL protein |
CTD |
PMID:12147693 |
|
NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456
|
|
G |
Slc6a11 |
solute carrier family 6 member 11 |
multiple interactions |
ISO |
Flufenamic Acid inhibits the reaction [SLC6A11 protein results in increased uptake of gamma-Aminobutyric Acid] |
CTD |
PMID:15981712 |
|
NCBI chr 4:147,297,972...147,413,319
Ensembl chr 4:147,297,969...147,413,443
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO EXP |
Flufenamic Acid inhibits the reaction [TNF protein results in increased expression of PTGS2 protein] Flufenamic Acid results in increased expression of TNF mRNA |
CTD |
PMID:10866999 PMID:15135310 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
multiple interactions increases activity |
ISO EXP |
[Flufenamic Acid results in increased activity of TRPC6 protein] which results in increased uptake of Calcium Flufenamic Acid inhibits the reaction [1-oleoyl-2-acetoyl-sn-glycerol promotes the reaction [TRPC6 protein results in increased uptake of Calcium]]; Flufenamic Acid inhibits the reaction [1-oleoyl-2-acetoyl-sn-glycerol promotes the reaction [TRPC6 protein results in increased uptake of Manganese]] |
CTD |
PMID:11535132 PMID:14551041 PMID:21562303 |
|
NCBI chr 8:5,759,387...5,864,000
Ensembl chr 8:5,758,935...5,828,092
|
|
G |
Trpm2 |
transient receptor potential cation channel, subfamily M, member 2 |
multiple interactions |
EXP |
Flufenamic Acid inhibits the reaction [Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]] |
CTD |
PMID:21900507 |
|
NCBI chr20:10,703,568...10,753,189
Ensembl chr20:10,707,014...10,753,181
|
|
G |
Trpm4 |
transient receptor potential cation channel, subfamily M, member 4 |
decreases activity |
ISO EXP |
Flufenamic Acid results in decreased activity of TRPM4 protein |
CTD |
PMID:16966582 PMID:17188667 |
|
NCBI chr 1:95,781,805...95,812,095
Ensembl chr 1:95,782,000...95,812,532
|
|